Wilfredo A. Rivera-Martínez, Departamento de Medicina Interna, Grupo de investigación GIMI, Universidad Libre, Cali, Colombia
Ma. Eugenia Casanova-Valderrama, Departamento de Medicina Interna, Grupo de investigación GIMI, Universidad Libre, Cali, Colombia
Lunévar Figueroa-Torregroza, Departamento de Medicina Interna, Grupo de investigación GIMI, Universidad Libre, Cali, Colombia
José M. Ocampo-Chaparro, Departamento de Medicina Interna, Grupo de investigación GIMI, Universidad Libre, Cali; Facultad de Salud, Departamento de Medicina Familiar, Universidad del Valle, Cali; Colombia
Aura Ma. Salazar-Solarte, Departamento de Epidemiología, Universidad Libre, Cali, Colombia
José Zambrano, Departamento de Medicina Interna, Universidad de Nariño, Pasto, Colombia
Jaime Gallo-Villegas, Facultad de Medicina, Universidad de Antioquia, Medellín; Centro Clínico y de Investigación SICOR, Medellín. Colombia
Dagnóvar Aristizábal-Ocampo, Centro Clínico y de Investigación SICOR, Medellín, Colombia
Introduction: It is unknown whether the selection of individualized pharmacological treatment according to arterial hypertension (AH) subtype leads to greater blood pressure (BP) control. Objective: To evaluate the association between the selection of pharmacological treatment based on AH subtype and BP control. Materials and method: This was a real-world cohort study that included subjects with a de novo diagnosis of AH who received anti-hypertensive pharmacological treatment following current guidelines. Retrospectively, patients were classified by AH subtype according to the pattern of systolic or diastolic predominance of AH. Also, appropriateness of the pharmacological treatment was assessed based on AH subtype and the underlying hemodynamics of each subtype. BP control at the follow-up, within the first 12 weeks after diagnosis, was defined as < 140/90 mmHg. Results: Among the subjects included in the study (n = 1397), the mean age was 52.4 ± 13.2. Initiation of appropriate anti-hypertensive pharmacological treatment was associated with greater BP control (OR 2.17; CI: 1.49-3.15; p < 0.001). The patients who did not reach BP control presented a higher frequency of divergent systolic-diastolic hypertension subtype and greater hemodynamic alterations. Conclusions: Appropriate selection of pharmacological treatment based on AH subtype is associated with better BP control in patients with newly diagnosed AH.
Keywords: Blood pressure. Hypertension. Personalized medicine. Systemic vascular resistance. Hemodynamics.
